StockData
Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc

VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3029% above fair value
$530.76−22.39 (-4.05%)

Close on Nov 3, 2026Market cap $134.53BP/E 30.9Yield –

Vertex Pharmaceuticals Alpine Immune Sciences by Year

Alpine Immune Sciences — General and administrative expense ($M) ($M)

Vertex Pharmaceuticals Alpine Immune Sciences: $22.2M in FY2023, up 23.7% from a year earlier. No newer figure appears in the documents we track.

Latest, FY2023
22.2
Period ended Dec 31, 2023
Change on a year earlier
+23.7%
18.0 in FY2022
History
6 years
Since FY2018
Sources
4
Documents cited below

Where the FY2023 figure comes from

Source: SEC Filing ↗

Reported in SEC XBRL (CIK 0001626199 Alpine Immune Sciences).

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedAlpine Immune Sciences — General and administrative expense ($M) ($M)Year on yearSource
FY2023Dec 31, 202322.2+23.7%SEC Filing ↗
FY2022Dec 31, 202218.0+23.4%SEC Filing ↗
FY2021Dec 31, 202114.6+33.6%SEC Filing ↗
FY2020Dec 31, 202010.9+15.1%SEC Filing ↗
FY2019Dec 31, 20199.47+13.3%SEC Filing ↗
FY2018Dec 31, 20188.36–SEC Filing ↗

Cite this data

StockData. (2026). Vertex Pharmaceuticals Alpine Immune Sciences ($M), annual FY2018–FY2023 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/alpine-ga-exp

See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.

See a number that looks wrong?